ARTICLE | Clinical News
FDA accepts resubmitted BLA for ADMA's RI-002
October 19, 2018 5:41 PM UTC
FDA accepted for review a resubmitted BLA from ADMA Biologics Inc. (NASDAQ:ADMA) for RI-002 to treat primary immune deficiency disease. The PDUFA date is April 2, 2019...
BCIQ Company Profiles